Treatment of Hidradenitis Suppurativa Using Etanercept

Inclusion Criteria: * Chronic HS for \> 6months defined as tender and/or painful, red nodules and/or plaques (confluent nodules) with or without scarring, foul odor, or draining sinuses clinically with HS * Localizes to skin folds including any of axillx, breast, abdomen and groin * active disease * Negative pregnancy test within 7 days before the first dose of study drug * Sexually active subjects of childbearing potential must agree to use medically acceptable form of contraception during screening and throughout the study Exclusion Criteria: * Concurrent active infection including tuberculosis * Concurrent therapy or therapy 30 days prior with systemic corticosteroids, systemic immunosuppressants, systemic retinoids or ant-TNF agents * Severe comorbidities (diabetes mellitus requiring insulin, Q F of any severity, MI, unstable angina eectoris, uncontrolled hypertension, oxygendependent severe pulmonary disease, history of cancer \*thin 5\_ years except cutaneous basal cell or squamous cell carcinoma or in situ cervical carcinoma, history of TB or TB exposure, chronic hepatitis B or C, SLE, history of multiple sclerosis, transverse myelitis, optic neuritis or epilepsy * Currently enrolled or enrolled within 90 days prior in any trial for treatment of HS * Known HIV positive * Contraindication to etanercept as defined in package insert